These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 34586531)

  • 1. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
    Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
    Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
    Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
    Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Tamaki N; Tada T; Kurosaki M; Yasui Y; Ochi H; Mashiba T; Sakamoto A; Marusawa H; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kobashi H; Kusakabe A; Furuta K; Arai H; Nonogi M; Ogawa C; Sato T; Tamada T; Nakamura S; Hasebe C; Tsuchiya K; Izumi N
    Invest New Drugs; 2022 Dec; 40(6):1290-1297. PubMed ID: 36152108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
    Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik YH
    Gut Liver; 2024 Jul; 18(4):709-718. PubMed ID: 38932499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
    Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
    United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
    Zhu AX; Dayyani F; Yen CJ; Ren Z; Bai Y; Meng Z; Pan H; Dillon P; Mhatre SK; Gaillard VE; Hernandez S; Kelley RK; Sangro B
    Clin Cancer Res; 2022 Aug; 28(16):3537-3545. PubMed ID: 35435967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Takeda S; Namisaki T; Tsuji Y; Fujimoto Y; Murata K; Enomoto M; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Inoue T; Kawaratani H; Akahane T; Mitoro A; Yoshiji H
    Anticancer Res; 2022 Nov; 42(11):5465-5473. PubMed ID: 36288892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
    Sugimoto R; Satoh T; Ueda A; Senju T; Tanaka Y; Yamashita S; Koyanagi T; Kurashige T; Higuchi N; Nakamura T; Tanaka M; Azuma Y; Ohno A; Ooho A; Ooe M; Mutsuki T; Uchimura K; Kuniyoshi M; Tada S; Aratake Y; Yoshimoto T; Yamashita N; Harada S; Nakamuta M; Motomura K; Kohjima M;
    Medicine (Baltimore); 2022 Oct; 101(40):e30871. PubMed ID: 36221372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
    Gao X; Zhao R; Ma H; Zuo S
    BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
    Takeuchi Y; Nouso K; Fujioka SI; Kariyama K; Kobashi H; Uematsu S; Moriya A; Hagihara H; Takabatake H; Nakamura S; Yabushita K; Kikuchi T; Oyama A; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A
    Cancer Med; 2023 Sep; 12(17):17559-17568. PubMed ID: 37537956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.